Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$14.99 +0.9%	$17.40	$13.40 ▼ $20.68	$2.50B	0.54	1.85 million shs	1.06 million shs
IBRX ImmunityBio	$2.78 -3.8%	$3.00	$2.28 ▼ $10.53	$2.37B	0.51	5.78 million shs	8.77 million shs
XENE Xenon Pharmaceuticals	$33.03 -1.2%	$35.28	$26.74 ▼ $46.00	$2.53B	1.21	433,674 shs	476,739 shs
XERS Xeris Biopharma	$4.38 +5.3%	$4.41	$1.69 ▼ $6.07	$674.26M	1.37	1.86 million shs	1.95 million shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	+1.92%	+1.71%	-15.09%	-12.07%	-13.30%
IBRX ImmunityBio	+9.89%	+6.25%	+0.70%	+24.57%	-43.44%
XENE Xenon Pharmaceuticals	+6.50%	+9.17%	-5.32%	-15.66%	-19.03%
XERS Xeris Biopharma	0.00%	-5.67%	-13.69%	+30.00%	+117.80%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	4.0204 of 5 stars	4.3	1.0	0.0	2.8	4.2	2.5
IBRX ImmunityBio	1.9327 of 5 stars	3.5	1.0	0.0	2.6	1.7	0.6
XENE Xenon Pharmaceuticals	1.9005 of 5 stars	3.5	1.0	0.0	2.8	2.5	0.0
XERS Xeris Biopharma	4.3173 of 5 stars	4.4	1.0	4.2	3.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.50	Moderate Buy	$23.93	59.66% Upside
IBRX ImmunityBio	3.00	Buy	$12.19	338.40% Upside
XENE Xenon Pharmaceuticals	3.00	Buy	$57.38	73.71% Upside
XERS Xeris Biopharma	2.80	Moderate Buy	$6.10	39.27% Upside

Current Analyst Ratings Breakdown

Latest XERS, XENE, ACAD, and IBRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/15/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
4/9/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
4/8/2025	ACAD ACADIA Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
3/31/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
3/13/2025	IBRX ImmunityBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
3/13/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
3/7/2025	ACAD ACADIA Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight	$20.00 ➝ $20.00
3/7/2025	XERS Xeris Biopharma	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$5.00 ➝ $6.00
3/7/2025	XERS Xeris Biopharma	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$5.00 ➝ $6.50
3/7/2025	XERS Xeris Biopharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$3.00 ➝ $4.00
3/7/2025	XERS Xeris Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.60 ➝ $8.00

(Data available from 4/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$957.80M	2.61	N/A	N/A	$2.63 per share	5.70
IBRX ImmunityBio	$14.75M	160.91	N/A	N/A	($0.88) per share	-3.16
XENE Xenon Pharmaceuticals	$9.43M	268.10	N/A	N/A	$14.18 per share	2.33
XERS Xeris Biopharma	$203.07M	3.32	N/A	N/A	($0.05) per share	-87.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	-$61.29M	$1.36	19.22	19.72	N/A	13.83%	25.83%	14.71%	5/6/2025 (Estimated)
IBRX ImmunityBio	-$583.20M	-$0.63	N/A	N/A	N/A	-8,016.83%	N/A	-110.02%	5/8/2025 (Estimated)
XENE Xenon Pharmaceuticals	-$182.39M	-$3.02	N/A	N/A	N/A	N/A	-24.69%	-23.68%	5/8/2025 (Estimated)
XERS Xeris Biopharma	-$62.26M	-$0.38	N/A	N/A	N/A	-33.69%	N/A	-17.38%	5/8/2025 (Estimated)

Latest XERS, XENE, ACAD, and IBRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	IBRX ImmunityBio	-$0.12	N/A	N/A	N/A	$17.50 million	N/A
5/8/2025	Q1 2025	XENE Xenon Pharmaceuticals	-$0.94	N/A	N/A	N/A	$1.64 million	N/A
5/8/2025	Q1 2025	XERS Xeris Biopharma	-$0.07	N/A	N/A	N/A	$57.61 million	N/A
3/3/2025	Q4 2024	IBRX ImmunityBio	-$0.26	-$0.15	+$0.11	-$0.09	$8.74 million	$7.55 million
2/27/2025	Q4 2024	XENE Xenon Pharmaceuticals	-$0.89	-$0.84	+$0.05	-$0.84	$0.31 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IBRX ImmunityBio	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
XERS Xeris Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.29	2.11
IBRX ImmunityBio	N/A	2.68	2.64
XENE Xenon Pharmaceuticals	N/A	22.21	22.21
XERS Xeris Biopharma	N/A	1.79	1.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
IBRX ImmunityBio	8.58%
XENE Xenon Pharmaceuticals	95.45%
XERS Xeris Biopharma	42.75%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	28.30%
IBRX ImmunityBio	83.40%
XENE Xenon Pharmaceuticals	5.52%
XERS Xeris Biopharma	4.56%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	166.79 million	119.30 million	Optionable
IBRX ImmunityBio	590	853.44 million	115.67 million	Optionable
XENE Xenon Pharmaceuticals	210	76.54 million	72.03 million	Optionable
XERS Xeris Biopharma	290	153.94 million	142.28 million	Optionable

XERS, XENE, ACAD, and IBRX Headlines

Recent News About These Companies

CenterBook Partners LP Sells 2,791,929 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

April 12 at 7:11 AM | marketbeat.com

Xeris Biopharma (NASDAQ:XERS) Trading Down 6.2% - Here's Why

April 3, 2025 | marketbeat.com

AIGH Capital Management LLC Acquires 389,192 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

March 31, 2025 | marketbeat.com

Xeris Announces Changes to Its Board of Directors

March 28, 2025 | finance.yahoo.com

Is Xeris Biopharma Holdings (XERS) The Hot Biotech Stock Under $5?

March 27, 2025 | msn.com

Xeris Biopharma (NASDAQ:XERS) Reaches New 1-Year High - Still a Buy?

March 25, 2025 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Has $581,000 Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

March 23, 2025 | marketbeat.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Insider Beth Hecht Sells 40,000 Shares

March 22, 2025 | marketbeat.com

Xeris Biopharma (NASDAQ:XERS) Trading Up 4.9% - Here's Why

March 22, 2025 | marketbeat.com

Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength?

March 20, 2025 | zacks.com

12 Best Stocks to Invest in for a Stock Market Game

March 20, 2025 | insidermonkey.com

Xeris enters a whole new market for one of its main pharma offerings

March 20, 2025 | chicagobusiness.com

Xeris Biopharma Holdings (XERS): Among the Best Stocks to Invest in for a Stock Market Game

March 19, 2025 | insidermonkey.com

Calculating The Fair Value Of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

March 18, 2025 | finance.yahoo.com

Xeris Biopharma (NASDAQ:XERS) Sets New 12-Month High - Still a Buy?

March 18, 2025 | marketbeat.com

FDA approves Xeris Biopharma’s sNDA of Gvoke VialDx as gastro diagnostic aid

March 17, 2025 | markets.businessinsider.com

Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid

March 17, 2025 | finance.yahoo.com

Globeflex Capital L P Takes $424,000 Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

March 17, 2025 | marketbeat.com

Xeris Biopharma: Low Risk, Low Excitement Solid Revenue Generator

March 16, 2025 | seekingalpha.com

Xeris Biopharma (NASDAQ:XERS) Sees Unusually-High Trading Volume - Here's What Happened

March 15, 2025 | marketbeat.com

Xeris Biopharma Holdings Share Price (XERS.US)

March 12, 2025 | lse.co.uk

New MarketBeat Followers Over Time

Media Sentiment Over Time

XERS, XENE, ACAD, and IBRX Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$14.99 +0.13 (+0.87%)

Closing price 04:00 PM Eastern

Extended Trading

$14.79 -0.20 (-1.33%)

As of 06:36 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

ImmunityBio NASDAQ:IBRX

$2.78 -0.11 (-3.81%)

Closing price 04:00 PM Eastern

Extended Trading

$2.74 -0.03 (-1.26%)

As of 07:58 PM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Xenon Pharmaceuticals NASDAQ:XENE

$33.03 -0.41 (-1.23%)

Closing price 04:00 PM Eastern

Extended Trading

$33.02 -0.02 (-0.05%)

As of 04:20 PM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Xeris Biopharma NASDAQ:XERS

$4.38 +0.22 (+5.29%)

Closing price 04:00 PM Eastern

Extended Trading

$4.46 +0.09 (+1.94%)

As of 07:13 PM Eastern

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time